Argenx US, Inc.
$14.1M 19,529 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Madrigal Pharmaceuticals
Madrigal Pharmaceuticals reported $13,990,298.03 across General Payments, Research, and Ownership to 19,606 physicians and teaching hospitals across 20,808 transactions.
- $14.0M Top 10% payer
- All-tracks total
- 20,808 Top 10% volume
- Transactions
- 19,606 Top 10% reach
- Recipients
- #133
- of 1,925 companies
Madrigal Pharmaceuticals reported $13,990,298.03 across all CMS Open Payments tracks (General + Research + Ownership) to 19,606 physicians and teaching hospitals in Program Year 2024 - ranking #133 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $4,487,923.64, averaging $713.57 per recipient.
How Madrigal Pharmaceuticals's $14.0M all-tracks total breaks down
Madrigal Pharmaceuticals's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
A
100/100
Total payments
A
100/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
A
100/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer madrigal-pharmaceuticals Madrigal Pharmaceuticals
$14.0M · #133/1,925 · 0.1% industry · PY2024
- TOT $14.0M
- RANK #133
- SHARE 0.1%
- TXN 20,808
- RCP 19,606
- CAT 8
- GEN $4.5M
- TOP1 2.4%
- PY 2024
Volume peers
Nearest volume peer: Argenx US, Inc. ($14.1M)
Madrigal Pharmaceuticals sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Madrigal Pharmaceuticals
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Madrigal Pharmaceuticals, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
Of the 8 general-payment categories charted below, "Compensation for Services Other Than Consulting" is the largest at $3.0M across 1,071 transactions, 67.2% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 8 types of general payments, Madrigal Pharmaceuticals's largest category was "Compensation for Services Other Than Consulting" at $3.0M - 67.2% of General Payments.
Madrigal Pharmaceuticals reports 8 general-payment categories - the top three are Compensation for Services Other Than Consulting (67.2%), Food and Beverage (17.2%), and Travel and Lodging (8.2%). The remaining 5 categories make up 7.4% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Madrigal Pharmaceuticals files across 8 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Madrigal Pharmaceuticals divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $3.0M | 1,071 | 67.2% |
| Food and Beverage | $774.1K | 17,111 | 17.2% |
| Travel and Lodging | $367.2K | 1,140 | 8.2% |
| Honoraria | $238.1K | 68 | 5.3% |
| Consulting Fee | $41.2K | 66 | 0.9% |
| Space Rental or Facility Fees | $40.8K | 7 | 0.9% |
| Education | $6.0K | 141 | 0.1% |
| Grant | $5.0K | 2 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $381,665.20 (8.5%) of $4,487,923.64 in this company's General Payments records across 8,963 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Madrigal Pharmaceuticals
The five named recipients with the highest reported General Payments from this company
- 1
Santiago Munoz
$108,335.69 across 94 reported transactions
- 2
Zahid Vahora
$86,245.77 across 61 reported transactions
- 3
Naim Alkhouri
$80,263.56 across 53 reported transactions
- 4
Julio Gutierrez
$53,664.69 across 45 reported transactions
- 5
Nadege Gunn
$53,155.49 across 54 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Madrigal Pharmaceuticals ranks #133 of 1,925 by total payments (top 7% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,762 of 1,838 by HHI (bottom 4% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Journey Medical Corporation : $64.6K total payments, HHI 55
- Eisai Inc. : $7.1M total payments, HHI 55
- Amgen Inc. : $44.9M total payments, HHI 55
- ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) : $10.8M total payments, HHI 52
- Mylan Specialty L.P. : $1.4M total payments, HHI 51
- Virtus Pharmaceuticals LLC : $19.8K total payments, HHI 50
- Madrigal Pharmaceuticals (this company) : $4.5M total payments, HHI 49
- Electronic Waveform Lab, Inc. : $32.0K total payments, HHI 47
- Avvisto Therapeutics, LLC : $8.9K total payments, HHI 47
- Neurocrine Biosciences, Inc. : $14.2M total payments, HHI 47
- W. L. Gore & Associates, Inc. : $5.4M total payments, HHI 47
- Aucta Pharmaceuticals, Inc. : $25.2K total payments, HHI 46
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Madrigal Pharmaceuticals's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Madrigal Pharmaceuticals.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Madrigal Pharmaceuticals.
Showing 6 of 1,924 companies with CMS-reported payment data.
Atricure, Inc.
$13.7M 28,870 recipients
Compare payment profiles
Lazurite Inc.
$13.6M 7 recipients
Compare payment profiles
Centinel Spine, LLC
$13.6M 858 recipients
Compare payment profiles
NovApproach Spine, LLC
$14.5M 178 recipients
Compare payment profiles
RxSight Inc
$14.5M 7,552 recipients
Compare payment profiles
Put this to use
Madrigal Pharmaceuticals ranks #133 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See where Madrigal Pharmaceuticals sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just Madrigal Pharmaceuticals. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.